Risk Adapted Therapy Utilizing Upfront Brentuximab Vedotin (Bv) and Rituximab (R) With Reduced Toxicity Chemotherapy in the Treatment of Children, Adolescents and Young Adults (CAYA) With Newly Diagnosed Hodgkin Lymphoma (HL)

Authors

Jessica Hochberg, New York Medical CollegeFollow
Liana Klejmont, New York Medical CollegeFollow
L HarrisonFollow
Allyson Flower, New York Medical CollegeFollow
Qiuhu Shi, New York Medical CollegeFollow
J Basso
Mitchell Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

June 2017

Journal Title

Pediatric Blood & Cancer

Department

Pediatrics

Second Department

Epidemiology and Community Health

Recommended Citation

Hochberg, J., Klejmont, L., Harrison, L., Flower, A., Shi, Q., Basso, J., & Cairo, M. (2017). Risk Adapted Therapy Utilizing Upfront Brentuximab Vedotin (Bv) and Rituximab (R) With Reduced Toxicity Chemotherapy in the Treatment of Children, Adolescents and Young Adults (CAYA) With Newly Diagnosed Hodgkin Lymphoma (HL). Pediatric Blood & Cancer, 64 (Suppl 1), S3. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/65